210 related articles for article (PubMed ID: 37166526)
1. Long-term effects of canagliflozin treatment on the skeleton of aged UM-HET3 mice.
Yildirim G; Bergamo ETP; Poudel SB; Ruff RR; Dixit M; Hu B; Mijares DQ; Witek L; Chlebek C; Harrison DE; Strong R; Miller RA; Ladiges W; Bromage TG; Rosen CJ; Yakar S
Geroscience; 2023 Jun; 45(3):1933-1951. PubMed ID: 37166526
[TBL] [Abstract][Full Text] [Related]
2. Canagliflozin, an SGLT2 inhibitor, corrects glycemic dysregulation in TallyHO model of T2D but only partially prevents bone deficits.
Thrailkill KM; Bunn RC; Uppuganti S; Ray P; Popescu I; Kalaitzoglou E; Fowlkes JL; Nyman JS
Bone; 2020 Dec; 141():115625. PubMed ID: 32890778
[TBL] [Abstract][Full Text] [Related]
3. Neuroprotective effects of Canagliflozin: Lessons from aged genetically diverse UM-HET3 mice.
Jayarathne HSM; Debarba LK; Jaboro JJ; Ginsburg BC; Miller RA; Sadagurski M
Aging Cell; 2022 Jul; 21(7):e13653. PubMed ID: 35707855
[TBL] [Abstract][Full Text] [Related]
4. The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetes.
Thrailkill KM; Nyman JS; Bunn RC; Uppuganti S; Thompson KL; Lumpkin CK; Kalaitzoglou E; Fowlkes JL
Bone; 2017 Jan; 94():141-151. PubMed ID: 27989651
[TBL] [Abstract][Full Text] [Related]
5. Sex-dependent effects of Canagliflozin on kidney protection in mice with combined hypertension-type 1 diabetes.
Trentin-Sonoda M; Cheff V; Gutsol A; Hébert RL
PLoS One; 2023; 18(12):e0295284. PubMed ID: 38055691
[TBL] [Abstract][Full Text] [Related]
6. Canagliflozin regulates metabolic reprogramming in diabetic kidney disease by inducing fasting-like and aestivation-like metabolic patterns.
Shao M; Chen D; Wang Q; Guo F; Wei F; Zhang W; Gan T; Luo Y; Fan X; Du P; Liu Y; Ma X; Ren G; Song Y; Zhao Y; Qin G
Diabetologia; 2024 Apr; 67(4):738-754. PubMed ID: 38236410
[TBL] [Abstract][Full Text] [Related]
7. SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA/2J male mice.
Thrailkill KM; Clay Bunn R; Nyman JS; Rettiganti MR; Cockrell GE; Wahl EC; Uppuganti S; Lumpkin CK; Fowlkes JL
Bone; 2016 Jan; 82():101-7. PubMed ID: 26211996
[TBL] [Abstract][Full Text] [Related]
8. Sodium-glucose cotransporter 2 inhibitor canagliflozin alleviates vascular calcification through suppression of nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 inflammasome.
Chen A; Lan Z; Li L; Xie L; Liu X; Yang X; Wang S; Liang Q; Dong Q; Feng L; Li Y; Ye Y; Fu M; Lu L; Yan J
Cardiovasc Res; 2023 Oct; 119(13):2368-2381. PubMed ID: 37523743
[TBL] [Abstract][Full Text] [Related]
9. Hypothalamic sex-specific metabolic shift by canagliflozin during aging.
Jayarathne HSM; Sullivan R; Stilgenbauer L; Debarba LK; Kuchumov A; Koshko L; Scofield S; Liu W; Ginsburg BC; Miller RA; Sadagurski M
Geroscience; 2024 May; ():. PubMed ID: 38801647
[TBL] [Abstract][Full Text] [Related]
10. Canagliflozin extends life span in genetically heterogeneous male but not female mice.
Miller RA; Harrison DE; Allison DB; Bogue M; Debarba L; Diaz V; Fernandez E; Galecki A; Garvey WT; Jayarathne H; Kumar N; Javors MA; Ladiges WC; Macchiarini F; Nelson J; Reifsnyder P; Rosenthal NA; Sadagurski M; Salmon AB; Smith DL; Snyder JM; Lombard DB; Strong R
JCI Insight; 2020 Nov; 5(21):. PubMed ID: 32990681
[TBL] [Abstract][Full Text] [Related]
11. Endogenous Glucose Production and Hormonal Changes in Response to Canagliflozin and Liraglutide Combination Therapy.
Martinez R; Al-Jobori H; Ali AM; Adams J; Abdul-Ghani M; Triplitt C; DeFronzo RA; Cersosimo E
Diabetes; 2018 Jun; 67(6):1182-1189. PubMed ID: 29602791
[TBL] [Abstract][Full Text] [Related]
12. Canagliflozin alleviates LPS-induced acute lung injury by modulating alveolar macrophage polarization.
Lin F; Song C; Zeng Y; Li Y; Li H; Liu B; Dai M; Pan P
Int Immunopharmacol; 2020 Nov; 88():106969. PubMed ID: 33182027
[TBL] [Abstract][Full Text] [Related]
13. Canagliflozin Prevents Intrarenal Angiotensinogen Augmentation and Mitigates Kidney Injury and Hypertension in Mouse Model of Type 2 Diabetes Mellitus.
Woods TC; Satou R; Miyata K; Katsurada A; Dugas CM; Klingenberg NC; Fonseca VA; Navar LG
Am J Nephrol; 2019; 49(4):331-342. PubMed ID: 30921791
[TBL] [Abstract][Full Text] [Related]
14. Sex-dependent effects of canagliflozin and dapagliflozin on hemostasis in normoglycemic and hyperglycemic mice.
Marcińczyk N; Misztal T; Chabielska E; Gromotowicz-Popławska A
Sci Rep; 2023 Jan; 13(1):932. PubMed ID: 36650229
[TBL] [Abstract][Full Text] [Related]
15. The antidiabetic SGLT2 inhibitor canagliflozin reduces mitochondrial metabolism in a model of skeletal muscle insulin resistance.
VanDerStad LR; Wyatt EC; Vaughan RA
Diabet Med; 2024 May; 41(5):e15271. PubMed ID: 38140911
[TBL] [Abstract][Full Text] [Related]
16. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na
Uthman L; Baartscheer A; Bleijlevens B; Schumacher CA; Fiolet JWT; Koeman A; Jancev M; Hollmann MW; Weber NC; Coronel R; Zuurbier CJ
Diabetologia; 2018 Mar; 61(3):722-726. PubMed ID: 29197997
[TBL] [Abstract][Full Text] [Related]
17. Effect of canagliflozin on the overall clinical state including insulin resistance in Japanese patients with type 2 diabetes mellitus.
Koike Y; Shirabe SI; Maeda H; Yoshimoto A; Arai K; Kumakura A; Hirao K; Terauchi Y
Diabetes Res Clin Pract; 2019 Mar; 149():140-146. PubMed ID: 30716347
[TBL] [Abstract][Full Text] [Related]
18. Streptozotocin-Treated High Fat Fed Mice: A New Type 2 Diabetes Model Used to Study Canagliflozin-Induced Alterations in Lipids and Lipoproteins.
Yu T; Sungelo MJ; Goldberg IJ; Wang H; Eckel RH
Horm Metab Res; 2017 May; 49(5):400-406. PubMed ID: 28395380
[TBL] [Abstract][Full Text] [Related]
19. Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus.
Blevins TC; Farooki A
Postgrad Med; 2017 Jan; 129(1):159-168. PubMed ID: 27894216
[TBL] [Abstract][Full Text] [Related]
20. Effect of Canagliflozin Compared With Sitagliptin on Serum Lipids in Patients with Type 2 Diabetes Mellitus and Heart Failure with Reduced Ejection Fraction: A Post-Hoc Analysis of the CANA-HF Study.
Dixon DL; Billingsley HE; Canada JM; Trankle CR; Kadariya D; Cooke R; Hart L; Van Tassell B; Abbate A; Carbone S
J Cardiovasc Pharmacol; 2021 Sep; 78(3):407-410. PubMed ID: 34132690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
